Merck to Buy Cidara in $9.2B Deal as Patent Deadline Looms
Affected assets and topics
Why it matters
Merck agreed to acquire Cidara Therapeutics for $9.2 billion, as it looks to offset the patent loss of its cancer drug Keytruda. Merck will pay $221.50 per share in cash, more than double the closing price, to acquire the biotech company. This deal is part of Merck's efforts to bolster its pipeline and mitigate potential losses.
Article tone
Expected market reaction
Market impact analysis based on bullish sentiment with 79% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 10941
Original source
Merck & Co. agreed to acquire Cidara Therapeutics Inc., a biotech company developing a flu treatment, as part of its ongoing efforts to make up for the upcoming patent loss of its blockbuster cancer drug Keytruda. Merck will pay $221.50 a share in cash for Cidara in a tender offer, more the twice Thursday’s closing price, for a total transaction value of about $9.2 billion, the companies said Friday in a statement. Bloomberg's Madison Muller joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)
Read the full article on Bloomberg
Original article published by Bloomberg on November 14, 2025. Analysis and insights provided by AnalystMarkets AI.